Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility

Exclusion Criteria

• •Patients admitted the ICU or anticipated to require ICU transfer
• •Anticipated length of hospital stay \<48 hours.
• •Evidence of hyperglycemic crises (diabetic ketoacidosis or hyperosmolar hyperglycemic state) at enrollment
• •Severely impaired renal function (eGFR \< 30 ml/min/1.73m2) or clinically significant liver failure
• •Severe anemia with hemoglobin \<7 g/dL
• •Evidence of hemodynamic instability
• •Hypoxia (SpO2 \<95% on supplemental oxygen)
• •Pre-admission or inpatient total daily insulin dose \>100 units
• •Mental condition rendering the participant unable to consent or answer questionnaires
• •Pregnant or breast feeding at time of enrollment
• •Unable or unwilling to use rapid-acting insulin analogs (Humalog, Admelog, Novolog or Apidra) during the study
• •Use of hydroxyurea or high-dose ascorbic acid (\>1g/day)
• •Coronavirus Disease 2019 (COVID-19) infection or person under investigation (PUI) on isolation precautions